Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Fenebrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche Unveils Data Behind BTK Inhibitor's Phase 3 MS Win
    Roche Unveils Data Behind BTK Inhibitor's Phase 3 MS Win

    09 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/roche-unveils-data-behind-btk-inhibitors-phase-3-multiple-sclerosis-win

    FIERCE BIOTECH
    09 Feb 2026
    Share Share
    Roche's Fenebrutinib Reduces Disability Progression In Primary
    Roche's Fenebrutinib Reduces Disability Progression In Primary

    07 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/07/3234177/0/en/Roche-s-fenebrutinib-is-the-first-investigational-medicine-in-over-a-decade-that-reduces-disability-progression-in-primary-progressive-multiple-sclerosis-PPMS.html

    GLOBENEWSWIRE
    07 Feb 2026
    Share Share
    Genentech's Fenebrutinib Reduces Disability Progression
    Genentech's Fenebrutinib Reduces Disability Progression

    07 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-07/genentech-s-fenebrutinib-is-the-first-investigational-medicine-in-over-a-decade-that-reduces-disabil

    PHARMIWEB
    07 Feb 2026
    Share Share
    Roche Prsent Ocrevus And Fenebrutinib Data at ECTRIMS 2025
    Roche Prsent Ocrevus And Fenebrutinib Data at ECTRIMS 2025

    24 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/24/3155202/0/en/Roche-presents-new-data-for-OCREVUS-and-fenebrutinib-across-broad-patient-populations-at-ECTRIMS-2025.html

    GLOBENEWSWIRE
    24 Sep 2025
    Share Share
    Genentech Unveils Ocrevus, Fenebrutinib Data At ECTRIMS 2025
    Genentech Unveils Ocrevus, Fenebrutinib Data At ECTRIMS 2025

    24 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250923346934/en/Genentech-Presents-New-Data-for-Ocrevus-and-Fenebrutinib-Across-Broad-Patient-Populations-at-ECTRIMS-2025

    BUSINESSWIRE
    24 Sep 2025
    Share Share
    Roche's Fenebrutinib Shows 2-Year Benefit in Relapsing Sclerosis
    Roche's Fenebrutinib Shows 2-Year Benefit in Relapsing Sclerosis

    29 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/30/3090815/0/en/Roche-s-fenebrutinib-maintains-near-complete-suppression-of-disease-activity-and-disability-progression-for-up-to-two-years-in-people-with-relapsing-multiple-sclerosis.html

    GLOBENEWSWIRE
    29 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.